Rena M Conti

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 7

Top Topics

Tyrosine Kinase

Affordable Care Act

Top Venues

Nature biotechnology

Journal of law and the biosciences

Harvard University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Harvard University Sep 01 2000 - Jun 01 2007

United States

PHD :: Interfaculty Initiative in Health Policy

Publications

Matthew Vogel, Pragya Kakani, Amitabh Chandra, Rena M Conti
Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act. Nature biotechnology 42 (3) (2024)
Matthew Vogel, Pragya Kakani, Amitabh Chandra, Rena M Conti
Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act. Nature biotechnology (2024)
Matthew Vogel, Pragya Kakani, Amitabh Chandra, Rena M Conti
Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act. Nature biotechnology 42 (3) (2024)
Matthew Vogel, Pragya Kakani, Amitabh Chandra, Rena M Conti
Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act. Nature biotechnology 42 (3) (2024)
Matthew Vogel, Pragya Kakani, Amitabh Chandra, Rena M Conti
Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act. Nature biotechnology 42 (3) (2024)
Chi Heem Wong, Dexin Li, Nina Wang, Jonathan Gruber, Andrew W Lo, Rena M Conti
The estimated annual financial impact of gene therapy in the United States. Gene therapy (2023)
Ernst R Berndt, Rena M Conti, Stephen J Murphy
The generic drug user fee amendments: an economic perspective. Journal of law and the biosciences 5 (1) (2018)